Darbepoetin alfa for the treatment of anemia in myelodysplastic syndromes: a post-marketing surveillance study in Japan.

Morita Y, Tsuji Y, Yasukawa T, Mitani K

Open source

DOI
10.1007/s12185-026-04227-w
Published
2026 May 18
Container
International journal of hematology
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s12185-026-04227-w,
  title = {Darbepoetin alfa for the treatment of anemia in myelodysplastic syndromes: a post-marketing surveillance study in Japan.},
  author = {Morita Y and Tsuji Y and Yasukawa T and Mitani K},
  year = {2026},
  journal = {International journal of hematology},
  doi = {10.1007/s12185-026-04227-w},
  url = {https://doi.org/10.1007/s12185-026-04227-w}
}

RIS

TY  - JOUR
TI  - Darbepoetin alfa for the treatment of anemia in myelodysplastic syndromes: a post-marketing surveillance study in Japan.
AU  - Morita Y
AU  - Tsuji Y
AU  - Yasukawa T
AU  - Mitani K
PY  - 2026
JO  - International journal of hematology
DO  - 10.1007/s12185-026-04227-w
UR  - https://doi.org/10.1007/s12185-026-04227-w
ER  - 

APA

Y, M., Y, T., T, Y., & K, M. (2026). Darbepoetin alfa for the treatment of anemia in myelodysplastic syndromes: a post-marketing surveillance study in Japan.. International journal of hematology. https://doi.org/10.1007/s12185-026-04227-w

Source records